Creative Biolabs today announced the upgrade of its next-generation drug discovery pipeline with integrated AI-driven ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

FACE binds to CD71 on the T‑cell surface in CAR T cell preparation, and post-infusion, the same FACE molecules attach to CD71 ...

Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

UCLA scientists have developed a next-generation CAR-T cell therapy that can overcome the immunosuppressive tumor ...

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...